MedTrace Logo

Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

NCT05204329 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2026-01-29

No results posted yet for this study

Summary

This study is a longitudinal assessment using a classic dose-escalation study design to assess the safety and maximal tolerated dose (MTD) of topical MSC Secretome eye drops. The study will be conducted at Illinois Eye and Ear Infirmary located at University of Illinois at Chicago. The study will use anterior segment Optical Coherence Tomography (OCT)/Scheimpflug Imaging, esthesiometry, and visual analogue scale (VAS) to assess treatment tolerability.

Conditions

  • Mesenchymal Stromal Cells
  • Cornea
  • Corneal Defect
  • Corneal Epithelium Defect

Interventions

BIOLOGICAL

MSC Secretome Eye Drops

MSC Secretome eye drop will be dispensed.

Sponsors & Collaborators

  • National Eye Institute (NEI)

    collaborator NIH

  • National Institutes of Health (NIH)

    collaborator NIH

  • University of Illinois at Chicago

    lead OTHER

Principal Investigators

  • Ali R Djalilian, MD · University of Illinois at Chicago

  • Charlotte E Joslin, OD, PhD · University of Illinois at Chicago

  • Elmer Y Tu, MD · University of Illinois at Chicago

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-24
Primary Completion
2024-11-08
Completion
2024-11-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05204329 on ClinicalTrials.gov